

## TH Announces that National Institute of Health will Support Study of EGRIFTA® in Non-HIV Patients with Non-Alcoholic Fatty Liver Disease

May 11, 2018

Theratechnologies Inc. (TSX: TH) today announced that the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (NIH) in the United States has awarded a grant to the Massachusetts General Hospital to conduct a study using EGRIFTA® in non-HIV patients suffering Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatosis Hepatosis (NAFLD-NASH).